All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Measuring disease modification in MPN clinical trials
Bookmark this article
The MPN Hub was pleased to speak to Jean-Jacques Kiladjian, Université de Paris and Hôpital Saint-Louis, Paris, FR and Tiziano Barbui, Papa Giovanni XXIII Hospital, Bergamo, IT. We asked about measuring disease modification in MPN clinical trials.
Barbui begins by discussing established response criteria and the multi-parameter context of disease modification in myeloproliferative neoplasms, summarizing surrogate and non-surrogate markers. He highlights the complex situation in myelofibrosis compared with polycythemia vera and essential thrombocytosis in this regard.
Kiladjian then raises the challenges around these parameters and opens a discussion on whether artificial intelligence would be useful for a more objective and standardized response assessment in clinical trials.
They also touch upon measuring the molecular response inflammation in disease modification.
Measuring disease modification in MPN clinical trials
Your opinion matters
9 votes - 2 days left ...
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox